Lexicon Pharmaceuticals, Inc.
corporate_fare Company Profile
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for LXRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for LXRX spans 10-Q, 8-K, SCHEDULE 13D/A, DEFA14A.
Recent high-impact activity:
- Lexicon Q3 10-Q: $183.2M Cash, Wider $46.8M Nine-Month Loss, Hercules Debt in Place
- Lexicon Q3 Revenue $11.3M; SONATA-HCM Fully Enrolled, Data Q1 2027
- Lexicon Posts $11.3M in Third-Quarter Revenue
- Sotagliflozin Shows Consistent Heart Failure Benefit Across Blood Pressure Levels
- Lexicon Banks Third $10M Milestone from Novo Nordisk as LX9851 Advances in Phase 1
Financial Snapshot
Short Interest & Short Volume
14.04 days to coverFINRA reported short interest of 25,877,882 shares in LXRX as of the October 30, 2026 settlement, a 3.1% decrease from the prior period — about 14.0 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of LXRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LXRX, detected from its recent SEC filings.
Warrant Share Resale Registration · Warrant Terms
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →